ArticleDiscover oncology2025
Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04645199 (National Longitudinal Cohort of Hematological Diseases), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
National Longitudinal Cohort of Hematological Diseases (NICHE)
Who cites it
4 citing papers in PubMed.
- Mitoxantrone synergies with tigecycline againstMicrobiology spectrum · 2026Article
- Article
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDespite the poor prognosis for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), an optimal treatment strategy remains undefined. Mitoxantrone (MIT) is widely used to treat R/R AML.
methodsThis prospective, single-center, open-label study assessed the efficacy and toxicity of mitoxantrone hydrochloride liposome (Lipo-MIT)-containing regimen therapy, intensified by adding cytarabine (Ara-C), cyclophosphamide (CTX) or other agents. The primary endpoint was composite complete remission (CRc), including complete remission (CR), complete remission with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS). The secondary endpoints included overall response rate (ORR), event-free survival (EFS), overall survival (OS), and safety.
resultsWe enrolled 20 patients (median, 38.50 years; range, 20.00-53.00 years) and treated them with a Lipo-MIT-containing regimen from April 29, 2022, to July 11, 2023. Twelve patients (60.00%) achieved CRc after one course of induction therapy, of which MAC (Lipo-MIT, Ara-C, CTX)-based regimen was the most commonly used (12/20, 60.00%) with a CRc rate of 66.67% (8/12). Additionally, 13 patients relapsed after allogeneic stem cell transplantation (allo-HSCT) with a CRc of 69.20% (9/13). The median follow-up time was 6.64 months, with a median OS of 9.99 months (range, 1.64-19.61; 95% confidence interval [CI], 2.05-17.92). Moreover, 95% patients experienced grade 3/4 hematologic treatment-related adverse events (TRAEs), including anemia (60.0%), thrombocytopenia (60.0%), leukopenia (65.0%), and neutropenia (55.0%). All patients experienced nonhematologic TRAEs, with 14 patients showing grade 3/4 toxicity.
conclusionThe Lipo-MIT-based regimens demonstrate preliminary efficacy in R/R AML, particularly in those who relapsed after allo-HSCT, though hematologic toxicity warrants careful monitoring. CLINICAL
trial registrationClinicaltrials.gov Identifier: NCT04645199 in November 27, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.